RO6874281

DRUG4 trials

Conditions

Breast CancerCancer of Head and NeckMetastatic MelanomaPancreatic AdenocarcinomaRenal Cell CarcinomaSolid Tumor

Phase 1

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

CompletedNCT02627274

Hoffmann-La RocheBreast Cancer, Cancer of Head and Neck, Solid Tumor

Start: 2015-12-07End: 2022-11-10Updated: 2022-11-22

Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

CompletedNCT03063762

Hoffmann-La RocheRenal Cell Carcinoma

Start: 2017-03-20End: 2021-06-14Updated: 2023-02-17

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

CompletedNCT03193190

Hoffmann-La RochePancreatic Adenocarcinoma

Start: 2017-07-05End: 2025-02-27Updated: 2025-11-21

A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma

CompletedNCT03875079

Hoffmann-La RocheMetastatic Melanoma

Start: 2019-06-24End: 2022-07-14Updated: 2024-10-03

2026-02-25

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma

Cancer Research Communications2025-02-012 citations

Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma

Clinical Cancer Research2024-10-182 citations

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.

2024-10-113 citations

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

Clinical Cancer Research2024-04-1721 citations

Abstract CT212: Phase Ib/II, global, open-label, randomized evaluation of atezolizumab (atezo) + etrumadenant (etruma) + chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC

Cancer Research2024-04-05

Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma

Cancer Medicine2023-05-034 citations

Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform

The Oncologist2023-03-2048 citations

Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).

Journal of Clinical Oncology2021-05-208 citations

259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC

Regular and Young Investigator Award Abstracts2020-11-012 citations

Abstract CT201: Phase Ib/II open-label, randomized evaluation of atezolizumab + cobimetinib vs control in MORPHEUS-NSCLC (non-small cell lung cancer), MORPHEUS-PDAC (pancreatic ductal adenocarcinoma) and MORPHEUS-GC (gastric cancer)

Cancer Research2020-08-154 citations

Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).

Journal of Clinical Oncology2020-05-208 citations

Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).

Journal of Clinical Oncology2020-02-017 citations

MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.

Journal of Clinical Oncology2019-01-2914 citations

Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)

Annals of Oncology2018-10-0119 citations

MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types

Annals of Oncology2018-10-0119 citations

Abstract 1747: Hyaluronan (HA) accumulation restricts CD8+ T cell numbers and skews tumor-associated macrophage (TAM) phenotype in mouse syngeneic pancreatic tumors

Cancer Research2018-07-01

Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).

Journal of Clinical Oncology2018-05-2040 citations

MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.

Journal of Clinical Oncology2018-05-208 citations

MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer.

Journal of Clinical Oncology2018-02-018 citations

RO6874281

Sponsors

Conditions

Phase 1

Related Papers